June 22, 2017
The implantation of two second-generation iStent inject devices and postoperative topical prostaglandin in eyes with open-angle glaucoma reduced mean IOP and medication use at 18 months, according to a study.
The prospective, nonrandomized, open-label study included 53 patients with open-angle glaucoma and preoperative IOP of 18 mm Hg to 30 mm Hg on two medications; IOP ranged from 22 mg to 38 mm Hg after medication washout. The patients were implanted with two iStent inject devices (Glaukos) and received postoperative topical travoprost. Patients were followed for 18 months, and medication washout was repeated at month 12.